Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of LX1001 in APOE4 Homozygote Alzheimer's Disease
NCT05400330Phase 1Active, not recruiting
- Sponsor
- Lexeo Therapeutics
- Start
- May 2023
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LX1001 in Alzheimer's disease (AD), sponsored by Lexeo Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events at 260 weeks and Incidence of serious adverse events at 260 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
LX1001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05400330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400330.